KellyAGoldsmithMD

Pediatric Hematology & Oncology • Atlanta, GA

Physician

Join to view full profile

Dr. Goldsmith is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Goldsmith's full profile

Already have an account?

Office
1405 Clifton Road
Children's Healthcare of Atlanta
Atlanta, GA 30322
Phone+1 404-785-1200
Is this information wrong?

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2002 - 2005
Children's Hospital of PhiladelphiaResidency, Pediatrics, 1999 - 2002
University of Alabama School of MedicineClass of 1999

Certifications & Licensure

GA State Medical License 2009 - 2025
PA State Medical License 2000 - 2010
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
Active, not recruiting
Phase 1
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01
Completed
Phase 2
MIBG With Dinutuximab +/- Vorinostat Start of enrollment: 2018 Sep 12
Active, not recruiting
Phase 1
Roles: Contact
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma Start of enrollment: 2023 Nov 06
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Neuroblastoma Biology Study Start of enrollment: 2011 Jul 01
Recruiting
Roles: Contact
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Start of enrollment: 2017 Sep 05
Active, not recruiting
Phase 1
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, ...> ;Nature medicine. 2023-04-03
9 citations
YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma
Jenny Shim, Jasmine Y. Lee, Hunter C. Jonus, Amanda R. Arnold, Robert W. Schnepp, Kaitlyn M. Janssen, Victor Maximov, Kelly C. Goldsmith> ;Cancer Research. 2020 Nov 1
3 citations
Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.
Ryan J Summers, Sharon M Castellino, Christopher C Porter, Tobey J MacDonald, Gargi D Basu, Szabolcs Szelinger, Manoj K Bhasin, Thomas Cash, Alexis B Carter, Robert Cr...> ;JCO Precision Oncology. 2022 Apr 1
59 citations
Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma
Kelly C. Goldsmith, Michael D. Hogarty> ;Cancer Letters. 2005 Oct 18
5 citations
Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancer.
Goldsmith Kc, Hogarty> ;Current Opinion in Investigational Drugs. 2009 Jun 1
12 citations
A 3D Bioprinted in vitro Model of Neuroblastoma Recapitulates Dynamic Tumor-Endothelial Cell Interactions Contributing to Solid Tumor Aggressive Behavior.
Liqun Ning, Jenny Shim, Martin L Tomov, Rui Liu, Riya Mehta, Andrew Mingee, Boeun Hwang, Linqi Jin, Athanasios Mantalaris, Chunhui Xu, Morteza Mahmoudi, Kelly C Goldsm...> ;Advanced Science. 2022 Aug 1
8 citations
Dissecting the cellular components ofγδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials.
Hunter C Jonus, Rebecca E Burnham, Andrew Ho, Adeiye A Pilgrim, Jenny Shim, Christopher B Doering, H Trent Spencer, Kelly C Goldsmith> ;Oncoimmunology. 2022 Jan 1
9 citations
Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance.
Jorida Çoku, David M Booth, Jan Skoda, Madison C Pedrotty, Jennifer Vogel, Kangning Liu, Annette Vu, Erica L Carpenter, Jamie C Ye, Michelle A Chen, Peter Dunbar, Eliz...> ;The EMBO Journal. 2022 Apr 19
3 citations
A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment.
Jenny Shim, Kelly C. Goldsmith> ;Cancers. 2021 Sep 16
26 citations
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report ...
Steven G. DuBois, M. Meaghan Granger, Susan Groshen, Denice D. Tsao-Wei, Lingyun Ji, Anasheh Shamirian, Scarlett Czarnecki, Fariba Goodarzian, Rachel Berkovich, Hiroyu...> ;Journal of Clinical Oncology. 2021 Jul 16
3 citations
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.
Lindy Vernooij, Laurel T. Bate-Eya, Lindy K. Alles, Jasmine Y. Lee, Bianca Koopmans, Hunter C. Jonus, Nil A. Schubert, Linda Schild, Daphne Lelieveld, David A. Egan, M...> ;Molecular Cancer Therapeutics. 2021 Apr 13
19 citations
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Muna Qayed, Thomas Cash, Mourad Tighiouart, Tobey J. MacDonald, Kelly C. Goldsmith, Rachel Tanos, Leslie S. Kean, Benjamin Watkins, Yvonne Suessmuth, Cynthia Wetmore, ...> ;Pediatric Blood & Cancer. 2020 Apr 1
4 citations
Multidisciplinary Care of Adult Wilms' Tumor During Pregnancy: A Case Report and Review of the Literature.
Jacqueline T. Brown, Lara R. Harik, Meagan S. Barbee, Natia Esiashvili, Martina L. Badell, Kelly C. Goldsmith, Viraj A. Master, Mehmet Asim Bilen> ;Clinical Genitourinary Cancer. 2020 Feb 1
6 citations
Mentors' perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group
Adam J. Esbenshade, Lisa S. Kahalley, Reto M. Baertschiger, Roshni Dasgupta, Kelly C. Goldsmith, Paul C. Nathan, Paul Harker-Murray, Carrie L. Kitko, Edward A. Kolb, E...> ;Pediatric Blood & Cancer. 2019 Jul 16
70 citations
Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma.
Victor Maximov, Zhihong Chen, Yun Wei, M. Hope Robinson, Cameron Herting, Nithya S. Shanmugam, Vasilisa A. Rudneva, Kelly C. Goldsmith, Tobey J. MacDonald, Paul A. Nor...> ;Nature Communications. 2019 Jun 3
18 citations
Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model.
Jaquelyn T. Zoine, Kristopher A. Knight, Lauren C. Fleischer, Kathryn S. Sutton, Kelly C. Goldsmith, Christopher B. Doering, H. Trent Spencer> ;Oncoimmunology. 2019 May 27
48 citations
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Steven G. DuBois, Yael P. Mosse, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid, Renee M. McGovern, S. Groshen, Rochelle Bagatell, John M. Maris, Clare J. Twist, Kelly ...> ;Clinical Cancer Research. 2018 Dec 15
7 citations
Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction.
Daniel V. Runco, Cassandra D. Josephson, Sunil S. Raikar, Kelly C. Goldsmith, Glen Lew, Melinda Pauly, Ross M. Fasano> ;Transfusion. 2018 May 1
44 citations
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.
Andrew E. Place, Kelly C. Goldsmith, Jean-Pierre Bourquin, Mignon L. Loh, Lia Gore, Daniel A. Morgenstern, Yeshwant D. Sanzgiri, David Hoffman, Ying Zhou, Jeremy A. Ro...> ;Future Oncology. 2018 Mar 29
31 citations
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.
Araz Marachelian, Judith G. Villablanca, Cathy W. Y. Liu, Betty Liu, Fariba Goodarzian, Hollie Lai, Hiroyuki Shimada, Hung C. Tran, Jaime A Parra, Richard Gallego, Nor...> ;Clinical Cancer Research. 2017 Sep 15
21 citations
Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement
Matthew J. Ferris, H. Danish, Jeffrey M. Switchenko, Claudia Deng, Bradley George, Kelly C. Goldsmith, Karen Wasilewski, W. Thomas Cash, Mohammad K. Khan, Bree R. Eato...> ;International Journal of Radiation Oncology, Biology, Physics. 2017 Mar 15
4 citations
Concurrent myeloid sarcoma, atypical teratoid/rhabdoid tumor, and hypereosinophilia in an infant with a germline SMARCB1 mutation.
Jonathan L. Metts, Sunita I. Park, Bruno P. Soares, Cindy Y Fong, Jaclyn A. Biegel, Kelly C. Goldsmith> ;Pediatric Blood & Cancer. 2017 Jan 23
48 citations
Phase II evaluation of sunitinib in the treatment of recurrent or refractory high‐grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021
Cynthia Wetmore, Vinay M. Daryani, Catherine A. Billups, James M. Boyett, Sarah Leary, Rachel Tanos, Kelly C. Goldsmith, Clinton F. Stewart, Susan M. Blaney, Amar Gajjar> ;Cancer Medicine. 2016 Jul 1
23 citations
Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma
Rachel Tanos, Dipan Karmali, Srilatha Nalluri, Kelly C. Goldsmith> ;BMC Cancer. 2016 Feb 13
19 citations
EGFR signaling defines Mcl-1 survival dependency in neuroblastoma
Srilatha Nalluri, Susan K. Peirce, Rachel Tanos, Haneen Abdella, Dipan Karmali, Michael D. Hogarty, Kelly C. Goldsmith> ;Cancer Biology & Therapy. 2015 Mar 10
Join now to see all

Press Mentions

Clinical Trial May Change the Paradigm of Care for Patients with ALK-Driven High-Risk NeuroblastomaApril 4th, 2023
$Researchers Show Lorlatinib Is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma$
Researchers Show Lorlatinib Is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk NeuroblastomaMarch 31st, 2023
Targeted Cancer Treatment Helps Georgia Boy Facing Advanced NeuroblastomaOctober 5th, 2022
Join now to see all